Madrid, October 31, 2023.
Personalized medicine leading companies, Massive Bio and Health in Code, have announced a groundbreaking collaboration. This partnership is set to redefine the cancer treatment by merging Massive Bio’s Artificial Intelligence (AI) capabilities with Health in Code’s advanced genomic testing.
This collaboration focuses on delivering personalized medicine to cancer patients, which is essential in the present era where precision oncology is becoming paramount. By incorporating biomarker testing and genomic data into clinical decision-making, both organizations aim to provide more accurate and individualized treatments for cancer patients.
The core of the collaboration lies in the goal to increase patient access to clinical trials and precision oncology. Integrating Health in Code’s state-of-the-art cancer genetic knowledge and testing capabilities with Massive Bio’s AI-driven prescreening tools are expected to improve health outcomes and significantly reduce costs. This union is promising, especially for patients in Spain, where Health in Code has a significant presence.
“By harnessing the power of AI and cutting-edge genomic testing, we’re stepping into a new frontier of oncology treatment. This collaboration is a testament to our commitment to offering cancer patients the best care possible, tailored to their unique genetic makeup,” said Toygun Onaran, CFO of Massive Bio.
The partnership between Massive Bio and Health in Code is not merely transactional but it is built on shared values and a commitment to groundbreaking research. Both organizations believe that this collaboration will set a new standard in cancer care, emphasizing a data-driven and patient-centric approach. They are planning a series of webinars and patient engagement events in the upcoming months to educate the public about the benefits of biomarker detection for personalized medicine and the breakthroughs this collaboration aims to achieve. This commitment to patient education and advocacy further underscores their collective dedication to transforming the future of oncology.
“Health in Code Group has always focused its effort on making available to clinicians state-of-the-art technology and all the knowledge necessary for the implementation of genetic biomarkers in cancer patient management. By collaborating with Massive Bio, we will facilitate oncology patients access to clinical trials, enabling them to benefit from precision medicine”, remarked Inés Calabria, PhD, Head of Oncology at Health in Code.
About Massive Bio
Massive Bio empowers cancer patients to find their best treatment options, using artificial intelligence to improve equitable access and precision targeting for clinical trial matching, drug matching, and drug development. Massive Bio combines its best-in-class AI platform with technology-enabled services to remove barriers in clinical trial enrollment, value-based oncology decisions, and data-driven cancer treatment. The company serves more than two dozen pharmaceutical companies, contract research organizations, and hospital networks, and has been awarded an SBIR contract by the National Cancer Institute. Massive Bio was founded in 2015 by clinical, technology, and M&A executives, and has a global presence with nearly 100 people in 12 countries.